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Abstract
Background: Burns are a painful and traumatic experience, particularly in children. Reduced pain and anxiety positively
influences re-epithelialisation rates in paediatric burn patients, however current literature fails to fully explain the effects of
pain and anxiety and their links with wound healing. This study will determine if Burnaid® hydrogel dressing is an effective
treatment for reducing pain in the acute period of a burn injury. It is hypothesised that a reduction in pain will then improve
re-epithelialisation time in comparison to plastic wrap, which is standard practice at our institution— a metropolitan tertiary
paediatric hospital located in Brisbane, Australia.
Methods/design: A randomised controlled trial will be conducted to assess the effectiveness of Burnaid® as an analgesic
adjunct to cold running water first aid for the treatment of paediatric burns. Participants will include children aged between 0
and 16 years with an acute thermal burn injury (total burn surface area < 20%) presenting to the Department of Emergency
within 24 h of the burn occurring. Participants will be randomised into one of two groups: (1) Burnaid® hydrogel (intervention
arm) or (2) plastic wrap (control arm). Participants will also be stratified into one of two groups based on factors that influence
pain intensity: (1) high pain risk or (2) low pain risk. High pain risk factors include foot burns, hot coal/ash/fire pit burns, burn
area greater than 5%, and circumferential burns. The primary outcome is the intervention’s effect on reducing acute pain.
Secondary outcomes include days to re-epithelialisation, pulse rate, temperature, salivary cortisol and α-amylase, anxiety, and
cost-effectiveness. Sample size calculations have shown that 36 participants will be recruited into each group.
Discussion: This study will provide comprehensive data on the analgesic properties of Burnaid® as an adjunct to first
aid for the treatment of acute paediatric thermal burns. If the intervention is effective in reducing pain, Burnaid®
will be integrated as standard practice within the hospital’s Department of Emergency. This study replicates a
real-world scenario in order to identify clinically significant analgesic and wound-healing effects.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12617001274369. Prospectively registered on
5 Sept 2017.
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Background
Paediatric burn injuries pose a major epidemiological
problem worldwide, with one-fourth of all burn injuries
occurring in children under the age of 16, the majority
of whom are under 5 years of age [1]. Comprehensive
management of burn wounds includes a challenging
spectrum of acute, chronic, traumatic and surgical
wounds with a wide range of anatomical locations and
depths. Improving acute paediatric burn management
is critical because untreated pain is thought to contrib-
ute to long-term sensory issues such as chronic pain,
paraesthesia, dysesthesia and psychological conditions
[2]. Moreover, optimal pain management may have sig-
nificant implications with respect to re-epithelialisation
rates in children with burn injuries [3].
Historically, burn injuries have been viewed as one of
the most severe forms of trauma, and burn pain is
considered one of the most severe forms of acute pain
[4, 5]. Burn treatment is also associated with significant
pain and distress, and current standard treatments for
such injuries have been insufficient in providing the
analgesic needs for paediatric patients [6–9]. Paediatric
burn patients undergo multiple painful and distressing
procedures during their wound care and rehabilitation,
which can cause severe long-term physiological and
emotional effects [2]. If acute pain is not adequately
managed, it can lead to altered long-term pain percep-
tion and maladaptive coping strategies, which can persist
into adulthood [10–13]. Previous research also suggests
that inadequate pain control can lead to the develop-
ment of anticipatory anxiety for future medical proce-
dures [9]. It is estimated that 10–20% of young patients
who have sustained a burn injury go on to develop
psychological disorders such as post-traumatic stress
disorder [13, 14]. Therefore, optimising pain manage-
ment during the acute phase of a paediatric burn is crit-
ical not only for the physical and cosmetic outcome of
the injury but also for the child’s well-being at the time
and in the long term.
First aid
Correct first aid in the acute phase of a burn is essential
for preventing further tissue damage, reducing pain in the
acute phase and improving time to re-epithelialisation
[15–20]. Immediate cooling via the use of cold running
water (CRW) between 2 °C and 15 °C for 20min (applied
within 3 h of the initial injury) is the recommended gold
standard first aid for thermal burns, according to the
Australian and New Zealand Burn Association [15, 17, 21,
22]. After adequate CRW the burn must be covered to
protect the wound, reduce pain and prevent hypothermia
[8]. The use of a hydrogel dressing that aids in cooling
and hydration to the burn wound could be an ideal
adjunct to current first aid practice. Advanced wound-
dressing technologies require clinical data to support their
use, and currently there is limited empirical evidence to
support the use of hydrogel dressings as an analgesic
adjunct to first aid for the treatment of acute burn injuries.
Moreover, there are no studies investigating the use of
these dressings in the paediatric burn population.
Use of hydrogels on burns
Current guidelines recommend burn wound covering
after CRW first aid [8]. Acute burn wound coverings are
required to be transparent and non-adherent and to
have high application and removal ease. Plastic wrap ful-
fils these criteria and, excluding applications to the face,
is a practical choice of dressing for acute burn injuries.
In comparison to plastic wrap, Burnaid® hydrogel dress-
ings (Mundicare, Sydney, Australia) may provide add-
itional pain relief via an evaporative cooling effect and
may thereby assist in wound healing [23–25]; however,
empirical evidence is still limited. The Burnaid® hydrogel
dressing comprises a 3-mm-thick, sterile, open foam
polyester urethane pad that is impregnated with a pro-
pylene glycol gel which contains more than 90% purified
water. Following the recognised standard of first aid
treatment for acute burn injuries, Burnaid® is recognised
as an adjunct to first aid whose aim is to reduce pain.
Moist interactive wound dressings provide pain relief
via an evaporative cooling effect and create a moist
environment which soothes exposed nerve endings in
the skin [26]. Hydrogel dressings provide a concomitant
cooling and wound-covering function and dissipate
heat from the burn wound, and dressings come in a
wide range of sizes which can be applied to all areas of
the body [23, 27, 28].
The use of hydrogel dressings as an acute treatment
for burn injuries has increased in the pre-hospital set-
ting over the past decade. Allison showed that 39% of
emergency medical services (EMS) in the United Kingdom
applied hydrogel dressings (e.g., Water-Jel, Water-Jel
Technologies, Carlstadt, NJ, USA; Burnshield, Levtrade,
Johannesburg, South Africa) during patient transport to
hospital for burn injuries [29]. Walker and colleagues
showed that 76% of UK fire and rescue services applied
hydrogel dressings to cover burns, whereas 23% used plas-
tic wrap as a burn wound dressing until EMS arrived [30].
Moreover, Cuttle and colleagues conducted an audit of
first aid interventions for paediatric burn patients present-
ing to a tertiary burns centre located in Brisbane,
Australia. This investigation found that Burnaid® hydrogel
dressings were applied by ambulance services in 12.9% of
cases [31]. In addition, authors of a 2013 retrospective
investigation reported that 5% of paediatric burns patients
who presented to a tertiary burns centre in Sydney,
Australia, had Burnaid® hydrogel dressings applied as a
first aid dressing [32]. A large retrospective investigation
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into pre-hospital paediatric burn care was conducted in
2014 using data from electronic ambulance response
forms for patients aged between 0 and 5 years who were
attended by the Queensland Ambulance Service from
2008 to 2010 [18]. Data were collected from 117 paediatric
burn incidents occurring within the Brisbane, Townsville
and Cairns regions. Burnaid® was the most commonly
used dressing during patient transport and was applied to
55.6% of all paediatric burn patients. Brisbane paramedics
applied Burnaid® dressings in 44.3% of paediatric burn
cases, whereas ambulance services in North and Far North
Queensland applied Burnaid® during patient transport in
72.7% and 60.9% of cases, respectively [18]. The difference
in rates of use between regions further exemplifies the
need for evidence-based guidelines for the use of hydrogel
dressings in burn patients.
In a clinical investigation in which researchers evalu-
ated the efficacy of hydrogel dressings in burn wound
care, it was reported that hydrogel dressings conform
well to the wound bed, are quick and easy to apply, and
allow for wound inspection through the dressing [33]. In
addition, it was observed that hydrogel dressings are
effective for providing hydration to deep partial thick-
ness burns and act to absorb exudate without becoming
adherent to the wound bed. It was further reported that
hydrogel sheet dressings are well tolerated by patients,
who report no pain associated with dressing changes or
between dressing changes [33]. The researchers in that
study also commented on the paucity of evidence for the
use of hydrogel dressings in burn care and their use in
major burn wounds. This demonstrates the need for
further investigation into the efficacy of hydrogel dress-
ings for the acute treatment of burn injuries, so that
evidence-based guidelines regarding their use and
application can be developed. The potential that hydro-
gel dressings can reduce pain during the acute burn
phase should not be underestimated in a clinical area
where pain is most probably at its greatest. The primary
aim of the present research is to assess the analgesic
properties of Burnaid® hydrogel dressings as an adjunct
to current first aid in comparison to plastic wrap, which
is currently used to cover burn injuries following CRW.
Effect of pain and inflammatory mediators on wound
healing
The association between pain and wound healing is
complex. In patients with significant tissue damage such
as a burn, there is a prolonged and intense release of
inflammatory mediators, and this can result in a state of
hyperexcitability, which leads to an increased perception
of pain [34]. It is evident that prolonged pain, such as
that experienced by patients with significant burn
injuries, can have maladaptive effects on wound healing
time [35] and individual pain thresholds [2]. Prolonged
release of inflammatory mediators from injured tissue
acts to sensitise the inflamed area to pain via lowering
the excitation threshold of nociceptors [34, 36]. This
lowering of activation threshold (hyperalgesia) results in
the perception of pain from typically non-painful stimuli
and is often the case in burn patients who report
increasing pain even where good progressive wound
healing has occurred [36]. This further demonstrates the
critical need to optimise pain management during the
acute phase of a paediatric burn.
Distraction, pain and wound healing
Several studies describe the relationship between
decreased pain and improved re-epithelialisation rates
in paediatric burn patients [3, 6, 37, 38]. A recent
randomised controlled trial assessed the effectiveness
of a procedural preparation and distraction device
(Ditto™; Diversionary Therapy Technologies, Toowong,
Australia) in reducing pain in paediatric burn patients
during burn wound care [3]. This trial found that children
who received the procedural preparation and distraction
treatment reported significantly lower procedural pain
scores (measured using the Wong-Baker Faces Pain Rat-
ing Scale) in comparison to patients who received stand-
ard care during their burn wound treatment (p ≤ 0.05).
Parent and caregiver observational reports of procedural
pain were also found to be lower in patients who received
the preparation and distraction device (p < 0.001).
Furthermore, children who received the Ditto™ device re-
epithelialised an average of 2.1 days faster than children in
the standard care group (CI, − 4.38, 0.10; p = 0.061).
Although not statistically significant, this result was clinic-
ally significant because the 2-day improvement rate in
re-epithelialisation in patients who received the Ditto™
treatment translated into a sizeable reduction in the need
for scar monitoring: 26% of patients in the Ditto™ treat-
ment group re-epithelialised beyond 14 days, in contrast
to 48% of participants in the standard practice group.
Objectives
The objective of the present study is to compare the ef-
fectiveness of plastic wrap (currently used to cover burns
following CRW at Lady Cilento Children’s Hospital
(LCCH; Brisbane) and Burnaid® hydrogel dressing to re-
duce pain intensity in children who have sustained a
burn injury prior to the application of a standard burns
dressing.
Hypotheses
It is hypothesised that Burnaid® is more effective than
plastic wrap at reducing pain intensity in the acute
burn phase. It is also hypothesised that decreased
pain experienced during the acute phase of the burn
injury will speed up wound healing time and will
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result in a clinically significant reduction in days to




A single-centre, superiority, two-arm, parallel-group ran-
domised controlled trial will be conducted to examine
the effectiveness of Burnaid® hydrogel dressing as an an-
algesic adjunct to first aid in comparison to plastic wrap.
The present study includes methods that have been
modelled on successful prior trials conducted by mem-
bers of this investigative team at the same participating
facility as the present trial [39, 40]. The Consolidated
Standards of Reporting Trials guidelines for randomised
controlled trials will be followed, and the protocol ad-
heres to the Standard Protocol Items: Recommendations
for Interventional Trials guidelines (SPIRIT; see checklist
in Additional file 1). Ethics approval for this project was
obtained from LCCH and The University of Queensland
human research ethics committees (HRECs). A flow dia-
gram of the trial is provided in Fig. 1.
Setting
Recruitment will be conducted in the Department of
Emergency (DEM) and Pegg Leditschke Children’s Burns
Centre Outpatient Department (OPD), located at LCCH,
Brisbane. LCCH is categorised as a level 6 service, pro-
viding tertiary-level care for the state’s most critically
and seriously injured children.
Inclusion criteria
Children recruited into the study will be aged between 0
and 16 years and will have acquired an acute thermal
burn injury that is < 20% of the total body surface area
(TBSA). The child must present to the DEM or burns
OPD within 24 h of sustaining the injury and must have
no silver dressing application prior to this admission.
Exclusion criteria
Exclusion criteria for mechanism of injury are chemical,
electrical, inhalation or friction burns; children who do
not arrive within 24 h of sustaining their acute burn injury;
children who do not receive appropriate first aid treat-
ment; children who received prior treatment of a silver
dressing or ointment; children who are non-English-
speaking; children with cognitive impairments; children
who are ventilated or require initial wound care in theatre
for debridement or grafting; current involvement with the
Department of Communities (child safety); children with
known sensitivity to hydrogels or hypersensitivity; and
children who have co-morbidities that would potentially
impair would healing (e.g., diabetes) or that may exacer-
bate itch and pain.
Recruitment
Treating physicians/nursing staff of all children meeting
the inclusion/exclusion criteria and presenting to the
LCCH, Brisbane, will determine eligibility for enrolment
in the study. Medical staff, once establishing the child’s
eligibility, will then notify the parents/guardians and
child of their eligibility to participant in the study. With
parent/caregiver permission an investigator aligned with
the study will discuss the trial with the parent/caregiver,
seek informed consent from the parent/caregiver, and
seek assent from the child (when appropriate). This trial
will use a stratified sampling method taking into account
factors which influence pain intensity in paediatric burn
patients, based on anecdotal evidence and observations
from paediatric burns surgeons and the unit’s experience
(unpublished hospital data audit). Once informed
consent is obtained participants will be stratified into
one of two groups: (1) high pain risk or (2) low pain risk.
Participants presenting to LCCH DEM or burns OPD
with one or more of the following criteria will be placed
into the high pain risk group:
 Foot burns (unilateral or bilateral)
 Hot coal/ash/fire pit burns
 Circumferential burns
 TBSA > 5%
All other participants who meet the inclusion criteria
for the trial but do not present with one or more of the
four aforementioned pain risks will be placed in the low
pain risk group. Following stratification, children will be
randomised to one of the two treatment groups. Ran-
domisation will be undertaken using a computerised
random number sequence-generating programme, and
treatment allocation will be masked by the use of sealed,
opaque, identical, serially numbered envelopes prepared
by an independent party. The researchers will not be
blinded to which group the child is in, because they will
be collecting set measures throughout the acute burn
period. At any point throughout the study period the
parent/guardian or child can withdraw from the study
without any implications for the child’s burn care, and
all withdrawals and discontinuations will be recorded.
Treatments
Intervention
Burnaid® hydrogel dressing will serve as the treatment
intervention in this trial. Paediatric burn patients rando-
mised to the intervention arm will have the hydrogel
dressing applied following 20min of CRW, and the dress-
ing will remain on the burn for a minimum of 20min.
Burnaid® will be applied as per the manufacturer’s instruc-
tions, followed by standard burn care, typically consisting
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of wound cleaning, debridement and silver dressing
application.
Control
Plastic wrap is the current acute wound covering applied
to thermal burn injuries at LCCH, and it will serve as
the control arm in this trial. Participants randomised to
receive plastic wrap will have the dressing applied after
first aid and will have the dressing remain on for a mini-
mum of 20min, followed by standard burn care.
Data collection
Information regarding patient demographics and clinical
details will be obtained from the parent/guardian, child
(where age appropriate), and patient chart to record
mechanism of injury, affected area, burn TBSA, what
first aid was provided, form of transport, and time to
presentation (see SPIRIT figure in Fig. 2). Apart from
which type of dressing the child is receiving prior to the
application of silver dressings, all participants will
receive the standard medical care as would those not in
the trial.
Following patient enrolment and randomisation, acute
measures will be collected in LCCH DEM. Acute measures
will include pain (measured using the Faces Pain Scale–Re-
vised [FPS-R]; Face, Legs, Activity, Cry, Consolability scale
[FLACC]; and visual analogue scale [VAS]), pulse rate,
temperature, respiratory rate, and salivary cortisol and
α-amylase, which will be recorded by the primary investiga-
tor. Acute measures will be collected before and after the
application of the randomised dressing and before and after
silver dressing application from the child, parent/guardian,
and nursing staff. In addition, peak FLACC scores during
wound cleaning and debridement will be documented, as
Fig. 1 Data collection flow diagram
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will all analgesia and distraction techniques. All participants
will have their burn wounds photographed using 3D
imaging after wound debridement in the DEM to assess
burn area. Patients (where appropriate) and parents/care-
givers will be sent home with a diary to record pain scores
and medications required prior to their first change of
dressing (COD), which will typically occur 3 days after
injury. Participants and parents/caregivers will be asked to
bring this home diary with them to their first dressing
change in the burns OPD.
Data collection in the burns OPD will continue
through to the child’s treating clinician classifying the
burn wound as 95% re-epithelialised. Measures collected
in the burns OPD at each dressing change appointment
will include pain (measured using FPS-R, FLACC, and
VAS), pulse rate, temperature, respiratory rate, and saliv-
ary cortisol and α-amylase at each dressing change
appointment. These measures will be collected before
and after silver dressing removal and before and after
the application of new silver dressings (see Fig. 4). Anx-
iety and itch will also be assessed at each COD appoint-
ment. At the first COD appointment, all participants
will have their burn wound scanned using a non-invasive
treatment referred to as laser Doppler imaging to meas-
ure burn depth and vascularity of the affected area. In
addition, all participants will have a 3D image of their
burn taken at each COD to assess the area of the wound
and its rate of re-epithelialisation.
Following wound re-epithelialisation and discharge
from the burns OPD, scar outcome will be assessed at 3
and 6months post-burn for all participants. At each 3-
and 6-month follow-up, patients will have their burn
wounds scanned using ultrasound to assess scar thick-
ness; 3D imaging to assess scar area; DSM ColorMeter
Fig. 2 SPIRIT figure. SPIRIT schedule of study recruitment, intervention and assessments. Allocation to the intervention group will occur in
the Department of Emergency at Lady Cilento Children’s Hospital upon patient admission following a thermal burn injury; t1 = 3–5 days
after burn injury and each subsequent dressing change; t2 = 3 months after burn injury; t3 = 6 months after burn injury
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(Cortex Technology, Hadsund, Denmark) to examine
scar colour and pigmentation; and Patient and Observer
Scar Assessment Scale (POSAS), Brisbane Burn Scar Im-
pact Profile (BBSIP) and Child Health Utility 9D Index
(CHU9D) to measure health-related quality of life. Thy
will also undergo itch assessment, and saliva samples
will be collected to examine baseline cortisol and α-
amylase levels.
Primary outcome measure
The primary outcome of this trial is pain intensity
after acute dressing application (see Measure 2 in
Fig. 3). Observational reports from nursing staff using
the FLACC scale will be used to measure this pri-
mary study outcome for all participants enrolled in
this trial.
Ancillary pain measures
Pain intensity will be assessed before and after hydrogel
dressing application and before and after silver dressing
application, using self-report scales, parental/carer-speci-
fic, and nursing-specific pain scales (see Fig. 3). The set
points of data collection will be recorded on a data
collection form for patient and external observers to
communicate pain intensity in a more accurate manner.
The three physiological and psychological age-specific
scales outlined below have been selected to allow assess-
ment of pain and distress.
1. The FPS–R will be used to assess pain in children
aged 4 years and older. The FPS–R is a self-rated,
self-administered scale that uses images of facial
expressions to assess pain intensity in children [41,
42]. The FPS–R has been shown to be superior to
other faces scales [43] and has been validated in
the literature as having a strong positive correlation
(r = 0.93) with the visual analogue scale for pain
(VAS-P) in children aged between 5 and 12 years
[44]. Authors of a systematic review of self-report
pain intensity measures for use in paediatric clinical
trials reported that the FPS–R appears to be the most
psychometrically sound pain assessment tool for
children aged between 4 and 12 years [42].
Furthermore, a 2010 systematic review of the
FPS–R for child self-reporting of pain intensity
concluded that the FPS–R is recommended as a
research tool because of the measure’s utility and
psychometric features [45].
2. The FLACC scale [46] will be used by nursing staff
to assess pain and distress levels. The FLACC is
an observational behavioural scale that has been
validated for pain assessment in children aged
between 2 months – 7 years [46]. Observational
pain scales such as the FLACC are widely used
in paediatric clinical research [47]. A prospective
observational investigation conducted in 2012
assessed the use of the FLACC scale to measure
pain and distress in patients aged between 6 and
42 months (N = 125). This study found that
FLACC scores can be high during non-painful
procedures, as well as during the restraining
phase of procedures [47]. These findings further
support the notion that the FLACC assesses a
composite of pain and distress in young
children.
3. VAS-P for children aged 8 years and older and
visual analogue scale observer (VASobs) for
parent/guardian reports will be used. These scales
have been chosen because they are age-specific
and reliable and have been validated in recent
literature. VASs have been validated and frequently
Fig. 3 Acute pain assessment in the Department of Emergency. Following cold running water first aid, pain will be assessed before and after the
application of the randomised dressing, peak pain scores during wound cleaning and debridement, and before and after silver dressing
application. Pain scores will be collected from the patient (where appropriate), observational pain scores will be collected from parents
and caregivers, and Face, Legs, Activity, Cry, Consolability scale scores will be collected from nursing staff
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used to measure pain in adult populations and in
paediatric populations as young as 5 years of age
[48–50]. When quantifying pain intensity in pre-
verbal and early-verbal children, who are unable
to self-report, the VASobs repeatedly appears in
the literature as a proxy for self-reports of pain
[50–52]. Earlier studies have demonstrated that
young burn patients can readily grasp the
concept of quantifying their pain using anchored
scales and even in moments of extreme
discomfort are able to continue giving pain
scores [53].
Physical measures of pain and distress will also be
recorded at each of the measurement points depicted
in Figs. 3 and 4. These measures include pulse rate,
respiratory rate and temperature because increases in
these physiological measures have been shown to be
indicative of pain and distress.
Secondary outcome measures
Days to re-epithelialisation
The number of days from the date of the initial burn
until 95% wound re-epithelialisation occurs, the sur-
face area of the affected area, and the percentage of
wound re-epithelialisation will be calculated using
three methods: (1) clinical judgment of the treating
consultant, (2) 3D photography (3D LifeViz™ System;
QuantifiCare, Valbonne, France) and analysis using
specialist computer software, and (3) blinded review
of the 3D photographs by a panel of burn specialists.
The 3D LifeViz™ System will be used to photograph
all burns upon first presentation to the hospital fol-
lowing wound debridement and at each subsequent
burns OPD visit for dressing changes and wound
care. This will be performed for all participants until
burn wounds are deemed to be 95% re-epithelialised
or are grafted. Research has found 3D photography to
be a valid and reliable measure of acute burn wound
surface area in an Australian paediatric population
[54, 55]. In order to ensure accurate measurement
calibration in the associated DermaPix™ software
package (QuantifiCare), a ruler will also be included
in all 3D photographs. The 3D images will be ana-
lysed by the primary investigator using the DermaPix
software programme to determine the surface area of
the burn and the area of re-epithelialisation of the
wound at each COD. A panel of burn specialists,
which will be composed of consultants and nursing
staff, will perform a blinded review of the 3D images
and will assess the level of re-epithelialisation and ap-
pearance of each participant’s burn, mapping out the
edges of the wound and all unhealed areas. We will
further examine concordance between the burn spe-
cialist’s clinical assessment and the DermaPix map-
ping programme regarding re-epithelialisation.
Staff and caregiver perspectives on dressings
Perception of ease of dressing application, removal, flexi-
bility, and conformity will be rated by medical and nurs-
ing staff using a self-reported 0–10 Numeric Rating
Scale (NRS) for both the Burnaid® hydrogel dressing and
plastic wrap groups. Clinical staff will also be surveyed
again using the same NRS after recruitment has ceased
in order to examine any changes in their perception of
either acute wound covering. In addition, parent/care-
giver and patient (when appropriate) perception of com-
fort, ease of movement, and ease of dressing application/
removal will be measured using an NRS. It is noted that
ease of dressing measurements in the DEM will be con-
founded owing to lack of blinding and as a result of the
variable nature, size, and anatomical location of the
areas to be dressed.
Fig. 4 Pain assessment during change of dressing follow-up appointments. All participants will have their pain assessed in the waiting
room of the Pegg Leditschke Children’s Burns Centre Outpatient Department prior to premedication for their follow-up dressing changes.
Pain scores will also be measured subsequent to silver dressing removal, prior to the application of new silver dressings, and after application of the
new silver dressing
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Scar/skin condition at 3 and 6months
At 3 and 6months after the date of injury, a face-to-face
follow-up will be performed with all participants (interven-
tion and standard care groups) to assess the skin and scar
characteristics of the affected area. This assessment will
involve (1) 3D camera imaging (3D LifeViz™ System),
which will be used to determine scar area and volume
above the skin; (2) ultrasound scanning (BT12 Venue 40
MSK; GE Healthcare, Chicago, IL, USA), which will be
used to measure the height of the scar; and (3) the POSAS
measurement tool, which will be used to assess scar sever-
ity. The POSAS will be completed with the patient (if aged
6 years or older) and the parent/caregiver, and it will docu-
ment observer scale items of scar thickness, vascularity,
pliability, pigmentation and relief in addition to patient
scale items of itch, pain, colour, stiffness, thickness and
irregularity. In addition, DSM II Skin ColorMeter analysis
will be performed to assess the lightness, redness or
erythema, and pigmentation of the scar. The DSM II Col-
orMeter is an objective tool that uses tri-stimulus reflect-
ance colourimetry and narrow-band photometry to assess
scar characteristics, and it has been demonstrated to have
inter-observer reliability intra-class correlation coefficients
of 0.94 for lightness, 0.94 for erythema and 0.83 for
pigmentation in scar assessment [56].
Pain frequency
The BBSIP will be used to assess the intensity and fre-
quency of sensations, including pain, tightness and dis-
comfort, in addition to health-related quality of life
attributes which are specific to individuals with burn
scars. The BBSIP provides unique insight into health-re-
lated quality of life in children with burn scarring, in
addition to the concerns of parents/caregivers of chil-
dren with burn scaring. It has been shown to have
preliminary content validity, and further research is
currently being conducted in children, adults and par-
ents/caregivers of children with burn scars [57].
Itch
The Toronto Paediatric Itch Scale (TPIS) will be used
to assess pruritus in patients younger than 5 years of
age. The TPIS is a behaviour-anchored post-burn itch
scale which has been demonstrated in the literature
to be a valid and reliable measurement tool with a
moderate inter-observer agreement (Cohen’s kappa of
0.52, p < 0.001) [58]. Parents/caregivers of patients
younger than 5 years old will complete the TPIS,
which rates itch behaviours on a scale of 0 (indicating
absence of itch) to 3 (which represents severe itch
with significant disruption). In addition to the afore-
mentioned factors, this scale was selected because it
has been shown to be user-friendly, intuitive and reli-
able for use in infants and children as young as 5
years old or less [58]. Participants 5 years of age and
older will self-report their itch intensity using a 0–10
NRS. In addition, all caregivers will complete the itch
component of the BBSIP. Itch will be assessed at the
first COD and each follow-up until the wound is
deemed re-epithelised, and it will also be assessed at
3- and 6-month reviews.
Health-related quality of life
The CHU9D is a generic preference-based instrument
designed for use in children and adolescents to assess
how their health affects their life. The CHU9D will
be used to measure health-related quality of life in a
way that is suitable for use in cost-utility analyses.
Dimensions of the CHU9D include worry, sadness,
pain, fatigue, annoyance, schoolwork/homework, sleep,
daily routine and ability to partake in activities.
Preference weights applied to these nine attributes
enable the calculation of a multi-attribute utility score
where 0 represents death and 1 represents full health
[59]. The CHU9D has been developed and validated
for young people aged between 7 and 17 years, and it
has been shown to have good construct validity
within an Australian adolescent population [60]. At
each 3- and 6-month post-burn follow-up, children will
self-complete the CHU9D as appropriate, and a parent/
caregiver proxy-report will be completed for all partici-
pants (children of all ages).
Stress and anxiety
Stress is a secondary outcome and will be quantified via
salivary cortisol and α-amylase. Salivary cortisol is often
used as a biomarker to assess stress response and is
considered to be a reliable index of hypothalamic-pitui-
tary-adrenal axis activity [61]. The measurement of cor-
tisol levels in saliva is the preferred method of
assessment for researchers, particularly in a paediatric
population; salivary analysis is non-invasive and pain-
free in comparison to blood sampling and therefore
does not induce additional stress and trauma (and po-
tentially higher cortisol) as occurs with serum sampling
[62]. Moreover, there is a strong correlation between
cortisol levels in saliva and unbound cortisol in plasma
[63]. Salivary α-amylase is also said to be a reliable,
valid and sensitive biomarker for stress-related changes
in the autonomic nervous system and is a proxy for
noradrenaline, which is a sign of sympathetic adreno-
medullary system activation [64].
Participants will place a SalivaBio Oral Swab™
(Salimetrics Europe Ltd., Newmarket, UK) under their
tongue for 2 min for saliva collection. Salivary stress bio-
markers will be collected at the following time points:
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1. At first presentation to the DEM or burns OPD
subsequent to the application of either Burnaid®
hydrogel dressings or plastic wrap
2. Immediately after the removal of the Burnaid® or
plastic wrap dressing
3. Before application of silver dressings
4. Immediately after the application of silver dressings
5. Immediately before premedication prior to the
patient’s first COD
6. Immediately before and after silver dressing
removal
7. After application of the new silver dressings
8. Three months after burn injury to obtain a baseline
Parents/caregivers and patients (where appropriate) will
also complete a saliva collection survey which documents
variables pertinent to salivary analysis. Such variables
include all medications given to the patient, time the
patient last woke up, time the patient last brushed their
teeth, all food/drink/gum consumed by the patient during
the previous hour, time the participant last consumed caf-
feine, pertinent smoking/tobacco history, and sample col-
lection time. The date, time and volume of saliva
collection will be recorded in the laboratory, and samples
will be refrigerated at 4 °C and processed within 3 days of
collection. Samples will be spun in a centrifuge at 1400 × g
at room temperature for 15min, and the saliva will be
frozen at − 80 °C until analysis. Salivary cortisol and
α-amylase will be quantified using enzyme-linked
immunosorbent assay kits (Stratech Scientific, Ely, UK),
with saliva samples analysed in triplicate to ensure accur-
ate results.
Healthcare resources and costs
Healthcare resource use will be collected from the per-
spective of a health service provider and costed at market
rates using methods that have previously been employed
in trials by members of this research team at this par-
ticipating centre [65, 66]. This includes recording trial
intervention-related resource use (e.g., the types and
amounts of acute wound dressings used) as well as
other burn-related healthcare resources that may be
important to a health service when deciding which of
the interventions to implement in clinical services pro-
viding care for children with acute burns. Clinician
labour time will be recorded for each participant and
costed at state award rates for each respective discipline.
Blinding
Owing to the nature of the trial, blinding will not be
possible, because treating clinicians, nursing staff,
patients and their families will be aware of the interven-
tion. The primary investigator will be present when the
acute wound dressings are being applied and removed to
obtain pain scores and additional measures from the
participant, caregiver and nursing staff. The acute
wound covering applied to each participant cannot be
masked within this environment, and therefore investi-
gator blinding will not be possible. In order to incorpor-
ate an element of blinding in the trial, an expert panel of
burn wound specialist will conduct a blinded review of
3D photographs for all participants to assess burn
wound depth and re-epithelialisation at each dressing
change until complete wound healing. Wherever pos-
sible during data collection analysis, treatment groups
will be de-identified.
Adverse effects
The proposed intervention is considered to be part of
standard pre-hospital care and is currently used by
Queensland Ambulance Services, despite Burnaid® prod-
ucts not being used at the LCCH DEM and burns OPD.
Therefore, minimal adverse events are expected. Known
potential adverse events (such as hypothermia, infection,
haematoma, excessive exudates, unpleasant sensations,
allergic reactions, chondritis, and disruption of the skin
on dressing removal) have a standardised management
protocol at LCCH DEM and burns OPD. In addition,
children with known adverse reactions to hydrogels will
be excluded from the trial. Adverse effects of the hydro-
gel dressing will be monitored by reviewing patient med-
ical records and via self-report data from parents/
caregivers, participants (where appropriate), and treating
clinicians. All adverse events will be reported to the
clinical health service and the overseeing HREC. If a
consultant believes that Burnaid® hydrogel dressings
were not appropriate for a patient’s treatment, discon-
tinuation or alteration of treatment will be at their
discretion, and data collection for such participants will
cease from that time point.
Data monitoring
Regular team meetings will be held to monitor the
progress of the study and set timelines and will allow for
any issues to be discussed and resolved. All data will
remain secure and de-identified, which the primary
investigator will ensure in addition to data cleansing and
circulation of results/outcomes.
Data storage
Collected electronic data will remain secure through
password protection on University of Queensland servers.
Filing cabinets containing patient data will remain locked
and secured within the swipe card-accessed Centre for
Children’s Health Research. All data collected for the
purpose of this investigation will be accessible only by the
primary investigator and approved names on the ethics
application form. Data collected and used for the trial will
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be de-identified, cleaned and checked. Any missing data
will be coded as missing, unknown or not applicable
before being locked for analysis. Data will remain secure
for 15 years as per the requirements of The University of
Queensland HREC.
Sample size
The sample size estimate was calculated on the basis of
the primary outcome of pain intensity after dressing
application. Previous researchers assessing paediatric
burn pain reported that pain scores within each subject
group were normally distributed with an SD of 2.4 [37].
To detect a significant between-group difference of 1.8
in pain scores after dressing application, 29 experimental
participants and 29 control participants will need to be
recruited in order to reject the null hypothesis that the
population means of the experimental and control groups
are equal with probability (power) of 0.8. The type I error
probability associated with the test of this null hypothesis
is 0.05. With up to a potential 20% loss to follow-up, the
calculated target sample size is equal to 72 participants.
LCCH treats approximately 25–34 children per month in
the DEM for acute burn injury. On the basis of these esti-
mates and a historical 70% success rate for trial recruit-
ment within LCCH, it is predicted that around 17 patients
will be recruited per month. Therefore, it is estimated that
data collection should be completed within 12months
from recruitment commencement.
Data analysis
The data set will be analysed using IBM SPSS Statistics
software (version 22; IBM, Armonk, NY, USA) and Stata
software (StataCorp, College Station, TX, USA). Descrip-
tive statistics will be calculated for all outcomes. Univari-
ate parametric analyses (e.g., t test, chi-square test) or
alternative non-parametric equivalent tests (e.g., Mann-
Whitney U test) will be used to assess differences
between groups at baseline where appropriate. Between-
group differences in outcomes will be analysed using
regression models. When analyses include multiple mea-
sures on the same participant, mixed effects methods
will be used to account for probable non-independence
in observations. When outcomes are on an interval
scale, linear models will be used. When outcomes are
binary, logistic models will be used, and when outcomes
are recorded as count data, Poisson models will be used.
Sensitivity analyses will be undertaken using multiple
imputation methods, where it can be assumed data are
missing at random. Analysis of differences between
groups, and also differences within groups over time, will
be undertaken. Analyses will be done on an intention-
to-treat basis. Significance will be set at p < 0.05.
Discussion
Pain and distress following first aid remains a major
challenge when treating acute paediatric burn injuries,
and literature shows that increased pain and stress can
have maladaptive effects on wound healing [35, 37, 67]
and patient outcomes [68]. Although Burnaid® hydrogel
dressings are frequently being used by Queensland
Ambulance Services during patient transport to hospital
for burn injuries [18], a limited number of high-level
studies have been conducted examining the clinical util-
ity of these dressings, particularly in relation to analgesic
properties and wound-healing effects. The widespread
use of hydrogel burn dressings (such as Burnaid®, Burn-
Shield®, and Water-Jel®) is alarming owing to the lack of
research supporting their use as a first aid dressing [69].
This randomised controlled trial will provide high-level
evidence to determine if Burnaid® hydrogel dressing pro-
vides superior pain relief in comparison to plastic wrap
as an acute burn wound covering applied after first aid
in paediatric patients with thermal burn injuries. Estab-
lishing which dressing is more effective in reducing
acute pain is critical to clinical care and also to facilitate
further evidence-based guidelines in this field.
Burns are a painful and traumatic experience, particu-
larly in children. Considering the adverse psychological
and physiological effects secondary to pain, optimal pain
management should be viewed as an essential and requis-
ite component in acute paediatric burn treatment [9].
Reduced pain and anxiety positively influences re-epithe-
lialisation rates [3], and time to re-epithelialisation is a
good predictor of scar outcome in patients with burn in-
juries [70]. This further validates attempts to speed up
re-epithelialisation rates. Even if hydrogel products are
more expensive than current standard acute wound cover-
ings, the cost of treating adverse scarring is substantial in
resources and time, as well as in cosmetic outcome for the
patient. Burnaid® hydrogel dressings have been shown to
be effective evaporative cooling agents, which is why these
dressings are hypothesised to have an analgesic effect
during acute burn care [69].
Trial status
Recruitment will commence at the beginning of Septem-
ber 2017, and it is expected that recruitment will take
approximately 12 months to complete, with final data
collection occurring in January 2019.
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